Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BMS-986158 · 2 trials · 2 indications
Number of participants experiencing different types of events, including Adverse Events (AEs), Serious Adverse Events (SAEs), AEs leading to discontinuation and deaths. Events are classified based on the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.
Number of participants experiencing abnormal hepatic function, as measured by different parameters. ALT = Alanine aminotransferase AST = Aspartate aminotransferase ULN = Upper Limit of Normal
| Arm | Type | Description |
|---|---|---|
| Part 1A: BMS-986158 + Ruxolitinib | EXPERIMENTAL | - |
| Part 1B: BMS-986158 + Fedratinib | EXPERIMENTAL | - |
| Part 2A1: BMS-986158 + Ruxolitinib | EXPERIMENTAL | - |
| Part 2B1: BMS-986158 + Fedratinib | EXPERIMENTAL | - |
| Part 2B2: BMS-986158 Mono and/or (BMS-986158 + Fedratinib), if applicable | EXPERIMENTAL | - |
| Part 2A2 Add-On: BMS-986158 + Ruxolitinib | EXPERIMENTAL | - |
| Part 2A3: BMS-986158 + Ruxolitinib | EXPERIMENTAL | - |
| Monotherapy Treatment | EXPERIMENTAL | Patients treated at various doses and schedules |
| Combination Therapy | EXPERIMENTAL | Patients treated at selected doses and schdules |
| Name | Type | Description |
|---|---|---|
| BMS-986158 | DRUG | Specified dose on specified days |
| Ruxolitinib | DRUG | Specified dose on specified days |
| Fedratinib | DRUG | Specified dose on specified days |
| Nivolumab | BIOLOGICAL | Specified dose on specified days |
Inclusion Criteria: * Diagnosis of primary myelofibrosis (PMF), post-essential thrombocythemia (ET) or post-polycythemia vera (PV) myelofibrosis * Treatment-related toxicities from prior therapy resolved to Grade 1 or pre-treatment baseline or determined to be irreversible prior to study treatment ...
BMS-986158 is an investigational small molecule being studied for the treatment of advanced tumors and myelofibrosis. It is in Phase 1 clinical development by Bristol-Myers Squibb. The drug is not approved and remains under investigation for these oncology indications.
BMS-986158 is a small molecule being developed by Bristol-Myers Squibb for oncology indications. Its specific molecular target has not been disclosed in available clinical trial information. The drug is being studied in advanced tumors and myelofibrosis.
BMS-986158 is being developed by Bristol-Myers Squibb Company, which trades under the ticker BMY. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with advanced cancers and myelofibrosis.
BMS-986158 is in Phase 1 clinical development. It is an investigational drug and has not received FDA approval. Clinical trials are ongoing or completed to assess its safety and tolerability in patients with advanced tumors and myelofibrosis.
BMS-986158 has been studied in two Phase 1 trials. NCT02419417, completed, enrolled 83 patients with advanced tumors. NCT04817007, active but not recruiting, is assessing the drug alone and with ruxolitinib or fedratinib in 216 participants with myelofibrosis.
BMS-986158 is a unique investigational compound developed by Bristol-Myers Squibb. No alternative names have been reported for this drug in clinical trial records. It is being studied as a monotherapy and in combination with other agents for blood cancers.